Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
radiopharmaceutical |
| gptkbp:activeIngredient |
samarium-153
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
V10BX02
|
| gptkbp:CASNumber |
150439-18-6
|
| gptkbp:containsElement |
samarium
|
| gptkbp:halfLife |
46.3 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
samarium lexidronam
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:ligand |
ethylenediaminetetramethylenephosphonate
|
| gptkbp:marketedAs |
gptkb:Quadramet
|
| gptkbp:mechanismOfAction |
beta particle emission
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:usedFor |
pain relief
bone metastases |
| gptkbp:bfsParent |
gptkb:Samarium-153
|
| gptkbp:bfsLayer |
8
|